Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology.
The deal also includes up to $750 million in future milestone payments – with the total value pretty impressive considering that Mariana’s RLT candidates are all still in preclinical development – but is yet more evidence of Novartis’ determination to become the leading player in the category.
